Skip to main content
. 2018 Aug 20;16(5):5882–5890. doi: 10.3892/ol.2018.9333

Figure 3.

Figure 3.

OS of (A) patients with MO and (B) patients with IM following treatment with HR or HRT. (A) P=0.019 and (B) P=0.132 (log-rank test). TACE, transcatheter arterialV chemoembolization; MO, multicentric occurrence; IM, intrahepatic metastases; HR, hepatic resection; HRT, HR plus adjuvant TACE; OS, overall survival.